Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer

被引：0
|
作者：
Cao, Hop S. Tran [1 ]
Bouvet, Michael [1 ]
Kaushal, Sharmeela [1 ]
Keleman, Alex [1 ]
Romney, Eric [1 ]
Kim, Ginna [1 ]
Fruehauf, John [1 ]
Imagawa, David K. [1 ]
Hoffman, Robert M. [2 ]
Katz, Matthew H. G. [3 ]
机构：
[1] Univ Calif San Diego, San Diego, CA 92103 USA
[2] AntiCancer Inc, San Diego, CA USA
[3] Univ Calif Irvine, Irvine, CA USA
来源：
CLINICAL & EXPERIMENTAL METASTASIS | 2011年 / 28卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：204 / 204
页数：1
相关论文
共 50 条
  • [31] Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis
    Saud A. Almawash
    Goutam Mondal
    Ram I. Mahato
    Pharmaceutical Research, 2018, 35
  • [32] Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors
    Chan, DC
    Earle, KA
    Zhao, TLM
    Helfrich, B
    Zeng, C
    Baron, A
    Whitehead, CM
    Piazza, G
    Pamukcu, R
    Thompson, WJ
    Alila, H
    Nelson, P
    Bunn, PA
    CLINICAL CANCER RESEARCH, 2002, 8 (03) : 904 - 912
  • [33] Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer
    Suzuki, Keiichi
    Aiura, Koichi
    Matsuda, Sachiko
    Itano, Osamu
    Takeuchi, Osamu
    Umezawa, Kazuo
    Kitagawa, Yuko
    CLINICAL & EXPERIMENTAL METASTASIS, 2013, 30 (04) : 381 - 392
  • [34] Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer
    Keiichi Suzuki
    Koichi Aiura
    Sachiko Matsuda
    Osamu Itano
    Osamu Takeuchi
    Kazuo Umezawa
    Yuko Kitagawa
    Clinical & Experimental Metastasis, 2013, 30 : 381 - 392
  • [35] Survival Benefit with the Combination of Docetaxel, Gemcitabine and Erlotinib in Advanced and/or Metastatic Pancreatic Cancer Patients
    Samelis, Georgios F.
    Ekmektzoglou, Konstantinos
    Tsiakou, Andriani
    Giannakaki, Styliani
    Konstadoulakis, Manoussos
    HEPATO-GASTROENTEROLOGY, 2011, 58 (110) : 1776 - 1781
  • [36] MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model
    Kawaguchi, Kei
    Igarashi, Kentaro
    Miyake, Kentaro
    Lwin, Thinzar M.
    Miyake, Masuyo
    Kiyuna, Tasuku
    Hwang, Ho Kyoung
    Murakami, Takashi
    Delong, Jonathan C.
    Singh, Shree Ram
    Clary, Bryan
    Bouvet, Michael
    Unno, Michiaki
    Hoffman, Robert M.
    TISSUE & CELL, 2018, 52 : 124 - 128
  • [37] Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis
    Schulz, P.
    Scholz, A.
    Rexin, A.
    Hauff, P.
    Schirner, M.
    Wiedenmann, B.
    Detjen, K.
    BRITISH JOURNAL OF CANCER, 2008, 99 (01) : 110 - 117
  • [38] Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis
    P Schulz
    A Scholz
    A Rexin
    P Hauff
    M Schirner
    B Wiedenmann
    K Detjen
    British Journal of Cancer, 2008, 99 : 110 - 117
  • [39] Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer
    Shevchenko, Ivan
    Karakhanova, Svetlana
    Soltek, Sabine
    Link, Julia
    Bayry, Jagadeesh
    Werner, Jens
    Umansky, Viktor
    Bazhin, Alexandr V.
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (01) : 98 - 107
  • [40] EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model
    Singh, Amit
    Xu, Jing
    Mattheolabakis, George
    Amiji, Mansoor
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2016, 12 (03) : 589 - 600
12345